At a glance
ClinicalIndex Comparison RecordPhase 3Active· 238 enrolled
Drug / intervention
inebilizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis
In Brief
A Phase 3 clinical trial evaluating inebilizumab and IV Placebo for Myasthenia Gravis. Active but no longer recruiting, targeting 238 participants across 104 sites in 19 countries.
Detailed Summary
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis
CountriesArgentina, Belarus, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Japan, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 3Active
202120222023202420252026202720282029
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionMay 2024
TodayJul 2026
Study CompletionJun 2029
First PostedAug 24, 2020
Enrollment StartOct 15, 2020
Primary CompletionMay 28, 2024
Study CompletionJun 7, 2029
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.9 years ago
Interventions
inebilizumabdrug
Participants will receive IV inebilizumab
IV Placebodrug
Participants will receive IV placebo matched to inebilizumab